137 related articles for article (PubMed ID: 12710199)
1. Use of tumor-activated hepatic stellate cell as a target for the preclinical testing of anti-angiogenic drugs against hepatic tumor development.
Olaso E; Vidal-Vanaclocha F
Methods Mol Med; 2003; 85():79-86. PubMed ID: 12710199
[No Abstract] [Full Text] [Related]
2. Proangiogenic role of tumor-activated hepatic stellate cells in experimental melanoma metastasis.
Olaso E; Salado C; Egilegor E; Gutierrez V; Santisteban A; Sancho-Bru P; Friedman SL; Vidal-Vanaclocha F
Hepatology; 2003 Mar; 37(3):674-85. PubMed ID: 12601365
[TBL] [Abstract][Full Text] [Related]
3. Anti-VEGF antibody in experimental hepatoblastoma: suppression of tumor growth and altered angiogenesis.
McCrudden KW; Hopkins B; Frischer J; Novikov A; Huang J; Kadenhe A; New T; Yokoi A; Yamashiro DJ; Kandel JJ; Middlesworth W
J Pediatr Surg; 2003 Mar; 38(3):308-14; discussion 308-14. PubMed ID: 12632340
[TBL] [Abstract][Full Text] [Related]
4. Vascular and haematopoietic stem cells: novel targets for anti-angiogenesis therapy?
Rafii S; Lyden D; Benezra R; Hattori K; Heissig B
Nat Rev Cancer; 2002 Nov; 2(11):826-35. PubMed ID: 12415253
[No Abstract] [Full Text] [Related]
5. SU5416 and SU6668 attenuate the angiogenic effects of radiation-induced tumor cell growth factor production and amplify the direct anti-endothelial action of radiation in vitro.
Abdollahi A; Lipson KE; Han X; Krempien R; Trinh T; Weber KJ; Hahnfeldt P; Hlatky L; Debus J; Howlett AR; Huber PE
Cancer Res; 2003 Jul; 63(13):3755-63. PubMed ID: 12839971
[TBL] [Abstract][Full Text] [Related]
6. Regulation of the pro-angiogenic microenvironment by carboxyamido-triazole.
Oliver VK; Patton AM; Desai S; Lorang D; Libutti SK; Kohn EC
J Cell Physiol; 2003 Oct; 197(1):139-48. PubMed ID: 12942550
[TBL] [Abstract][Full Text] [Related]
7. Regulators of angiogenesis as targets for anti-angiogenic tumor therapy.
Breier G; Heidenreich R; Gaumann A; Groot M; Licht A; Nicolaus A; Schmitz J; Reichmann E; Plate KH; Vajkoczy P
Ann Hematol; 2002; 81 Suppl 2():S71-2. PubMed ID: 12611084
[No Abstract] [Full Text] [Related]
8. [Molecular mechanisms of vasculogenesis and angiogenesis. What regulates vascular growth?].
Joussen AM; Kirchhof B; Gottstein C
Ophthalmologe; 2003 Apr; 100(4):284-91. PubMed ID: 12682760
[TBL] [Abstract][Full Text] [Related]
9. Vascular endothelial growth factor and anti-angiogenic peptides as therapeutic and investigational molecules.
Zachary I
IDrugs; 2003 Mar; 6(3):224-31. PubMed ID: 12789611
[TBL] [Abstract][Full Text] [Related]
10. Molecular control of physiological skin angiogenesis.
Odorisio T; Failla CM; Zambruno G
Eur J Dermatol; 2002; 12(6):VII-X. PubMed ID: 12506892
[No Abstract] [Full Text] [Related]
11. Inflammatory response of tumor-activated hepatic sinusoidal endothelium as a target for the screening of metastasis chemopreventive drugs.
Mendoza L; Vidal-Vanaclocha F
Methods Mol Med; 2003; 85():107-15. PubMed ID: 12710201
[No Abstract] [Full Text] [Related]
12. Ganoderma tsugae extract inhibits expression of epidermal growth factor receptor and angiogenesis in human epidermoid carcinoma cells: In vitro and in vivo.
Hsu SC; Ou CC; Chuang TC; Li JW; Lee YJ; Wang V; Liu JY; Chen CS; Lin SC; Kao MC
Cancer Lett; 2009 Aug; 281(1):108-16. PubMed ID: 19332363
[TBL] [Abstract][Full Text] [Related]
13. Pericytes and vessel maturation during tumor angiogenesis and metastasis.
Raza A; Franklin MJ; Dudek AZ
Am J Hematol; 2010 Aug; 85(8):593-8. PubMed ID: 20540157
[TBL] [Abstract][Full Text] [Related]
14. Expressions of vascular endothelial growth factor and angiopoietin-2 in myeloma cells.
Uneda S; Matsuno F; Sonoki T; Tniguchi I; Kawano F; Hata H
Haematologica; 2003 Jan; 88(1):113-5. PubMed ID: 12551836
[No Abstract] [Full Text] [Related]
15. Combination therapy with paclitaxel and thalidomide inhibits angiogenesis and growth of human colon cancer xenograft in mice.
Fujii T; Tachibana M; Dhar DK; Ueda S; Kinugasa S; Yoshimura H; Kohno H; Nagasue N
Anticancer Res; 2003; 23(3B):2405-11. PubMed ID: 12894521
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic targeting of the endothelin a receptor in human ovarian carcinoma.
Rosanò L; Spinella F; Salani D; Di Castro V; Venuti A; Nicotra MR; Natali PG; Bagnato A
Cancer Res; 2003 May; 63(10):2447-53. PubMed ID: 12750265
[TBL] [Abstract][Full Text] [Related]
17. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
[TBL] [Abstract][Full Text] [Related]
18. Pericytes from human non-small cell lung carcinomas: an attractive target for anti-angiogenic therapy.
Bagley RG; Rouleau C; Morgenbesser SD; Weber W; Cook BP; Shankara S; Madden SL; Teicher BA
Microvasc Res; 2006 May; 71(3):163-74. PubMed ID: 16624341
[TBL] [Abstract][Full Text] [Related]
19. Antiangiogenic and antitumor activities of peptide inhibiting the vascular endothelial growth factor binding to neuropilin-1.
Starzec A; Vassy R; Martin A; Lecouvey M; Di Benedetto M; Crépin M; Perret GY
Life Sci; 2006 Nov; 79(25):2370-81. PubMed ID: 16959272
[TBL] [Abstract][Full Text] [Related]
20. Circulating angiogenic growth factor levels in mice bearing human tumors using Luminex Multiplex technology.
Keyes KA; Mann L; Cox K; Treadway P; Iversen P; Chen YF; Teicher BA
Cancer Chemother Pharmacol; 2003 Apr; 51(4):321-7. PubMed ID: 12721760
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
